Browsing Tag
Pharmaceutical Manufacturing
36 posts
Alkem Laboratories (NSE: ALKEM) expands EU GMP-certified manufacturing network and commits Rs 533cr to Ujjain greenfield plant
Alkem Laboratories secures EU GMP approval for Daman plant and commits INR 533 crore to a greenfield facility in Ujjain's DMIC corridor. Read the full strategic analysis.
Ramky Infrastructure (NSE: RAMKY) secures Rs 3,000cr Maharashtra pharma park concession, lifting order book to Rs 13,500cr
Ramky Infrastructure (NSE: RAMKY) secures a 95-year INR 3,000 crore pharma park concession in Maharashtra. Read the full strategic and financial analysis.
CSL (ASX:CSL) breaks ground on $1.5bn Kankakee plasma plant expansion, betting patented Horizon 2 technology can widen its immunoglobulin lead
CSL (ASX:CSL) breaks ground on a $1.5B Kankakee plasma plant expansion using patented Horizon 2 yield tech. Read the full strategic analysis.
How India’s Rs 1.91 lakh crore PLI Scheme is structurally reshaping manufacturing across 14 strategic sectors
India’s ₹1.91 lakh crore Production Linked Incentive Scheme shows rising investments, exports, and localisation. Read how it is reshaping manufacturing.
Why Eli Lilly and Company is stockpiling a weight loss pill before the FDA has even said yes
Eli Lilly and Company is ramping inventory ahead of a key FDA decision on its oral weight loss pill. Find out what this signals for obesity drugs and investors.
AbbVie strengthens U.S. manufacturing strategy with Arizona facility deal, reinforcing long-term supply resilience
Find out how AbbVie’s Arizona manufacturing acquisition strengthens U.S. drug production and reinforces long-term supply resilience.
How Cosette Pharmaceuticals used CGT exclusivity to unlock a long-ignored ear infection drug market
Cosette Pharmaceuticals secures FDA approval with CGT exclusivity for a long-protected otic drug. Read what this signals for specialty generics.
EC clears €47m German aid for Vetter Pharma’s new manufacturing hub
EU approves €47m in German state aid for Vetter Pharma’s Saarlouis plant. Learn how this supports pharma jobs, injectables, and regional strategy.
Australia kills Cosette’s Mayne Pharma (ASX: MYX) buyout—citing drug supply risk and sovereignty
Australia blocks Cosette’s $430M bid to acquire Mayne Pharma, citing critical medicine supply risks. Find out what triggered the decision and future implications.
Lupin (NSE: LUPIN) goes big in the U.S.—$250m Coral Springs facility sparks investor buzz
Find out how Lupin’s $250 million Coral Springs manufacturing facility could redefine America’s respiratory drug security and boost U.S. pharma resilience.